Understanding off-target ADC lung toxicity: why human-relevant models matter

In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity.

Date: 20/03/2026
Author ImmuONE
DateCategory Watch Time 13 minutes In the first session of our Season 2 ImmuBYTES webinar series, Principal Scientist, Josephine Joel explores one of the biggest challenges in antibody-drug conjugate development: off-target lung toxicity. As ADC formats become more complex, the need for earlier, more mechanistic safety insight becomes more important. This session looks at why interstitial lung disease remains such a difficult risk to predict, why alveolar macrophages are central to the story, and how human-relevant in vitro models can help teams make safer, more informed decisions earlier in development.

Watch the full webinar

Watch the full session below to learn more about the biology behind ADC-related lung toxicity and the emerging tools that could help improve early safety assessment.

Speak to the team

If you would like to discuss ADC lung safety, pulmonary risk assessment or human-relevant in vitro models, get in touch with the ImmuONE team.

Add a Comment

Related Posts